검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | TCR (E6 T Cell Receptor, E6 T Cell Receptor (TCR)) iCell Gene Therapeutics·Human Papillomavirus ORR 0% |
|---|---|
Overview Program | E6 T Cell Receptor (TCR) |
Overview Company | iCell Gene Therapeutics |
Overview Modality | CGT |
Overview Target | Human Papillomavirus |
Overview Indication | Human Papillomavirus; HPV-16 |
Overview Phase | PHASE_1 |
Overview Status | DISCONTINUED |
MoA Mechanism | , using healthy donor peripheral blood mononuclear cells (PBMC) and MDS patient PBMC and bone marrow samples |
MoA Biomarker | PD-1 treatment in shaping tumor-regional CD39 + CD8 + T cells high |
PK/PD Species | Mouse, However |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse, However |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Mucosal-associated invariant T cells recognize a tumor-derived metabolite in the DNA synthesis pathway.. Mucosal-associated invariant T (MAIT) cells recognize metabolite-derived ligands, but the identity of such ligands in the context of cancer remains poorly defined. Herein, we demonstrate that the tumor-derived metabolite 5-formyl tetrahydrofolate (5-formyl THF), which is an intermediate of the … |
Toxicology CRS | Reported |
Clinical ORR | 0% |
Clinical Result source | ClinicalTrials.gov NCT02280811 |
Clinical Data Tier / Score | A · 9 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 12일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | TCR (E6 T Cell Receptor, E6 T Cell Receptor (TCR)) iCell Gene Therapeutics·Human Papillomavirus ORR 0% |
|---|---|
Overview Program | E6 T Cell Receptor (TCR) |
Overview Company | iCell Gene Therapeutics |
Overview Modality | CGT |
Overview Target | Human Papillomavirus |
Overview Indication | Human Papillomavirus; HPV-16 |
Overview Phase | PHASE_1 |
Overview Status | DISCONTINUED |
MoA Mechanism | , using healthy donor peripheral blood mononuclear cells (PBMC) and MDS patient PBMC and bone marrow samples |
MoA Biomarker | PD-1 treatment in shaping tumor-regional CD39 + CD8 + T cells high |
PK/PD Species | Mouse, However |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse, However |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Mucosal-associated invariant T cells recognize a tumor-derived metabolite in the DNA synthesis pathway.. Mucosal-associated invariant T (MAIT) cells recognize metabolite-derived ligands, but the identity of such ligands in the context of cancer remains poorly defined. Herein, we demonstrate that the tumor-derived metabolite 5-formyl tetrahydrofolate (5-formyl THF), which is an intermediate of the … |
Toxicology CRS | Reported |
Clinical ORR | 0% |
Clinical Result source | ClinicalTrials.gov NCT02280811 |
Clinical Data Tier / Score | A · 9 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 12일 (1일 전) |
추천 비교
추천 비교